Contact us for more information

Stephen J. PettiStephen J. Petti, R.N., BSN, BBA, FAHA
Co-Founder and CEO

Stephen J. Petti is the Company's Co-Founder and Chief Executive Officer. He was formerly the Founder and CEO of Blue Note Pharmaceuticals, Empire Pharmaceuticals (acquired by a publicly traded company in 2004), where Mr. Petti went on to lead the Company's stroke program and served as President of the subsidiary business entity that was created post-merger. As a Co-Founder, Mr. Petti participated in the start-up phase of DOV Pharmaceutical, a CNS specialty Pharma company, which he helped guide from first money through IPO in the space of three years. While at DOV he also served as the President of two major product development collaborations involving Elan and Biovail. Mr. Petti has 25+ years of international clinical drug development experience in a variety of settings that include Big- Mid- and Small- Pharma entities and major CROs. Over the course of his career he has participated in six successful NDAs/PLAs over a wide range of therapeutic areas and clinical indications. In the CRO arena, he served as Vice President of Global Clinical Consulting at Barnett International, a subsidiary of Parexel International, in the process establishing the company's first overseas office in Paris, the headquarters from which he managed the company's European operations. A former critical-care R.N. (BSN), Mr. Petti is a Fellow of the American Heart Association (FAHA) and the Stroke Council and a member of the American Society of Hypertension and the Society of Critical Care Medicine. He is active in entrepreneurial mentorship through Rensselaer Polytechnic Institute in Troy, NY and served as former CEO and Board Chairman for Vital Vio, Inc., a company developing a unique form of bactericidal lighting.

Email him at

Laurence Katz, M.D.Laurence M. Katz, M.D.
Co-Founder, Chief Medical/Scientific Officer

Laurence M. Katz, M.D., is Hibernaid's Co-Founder and serves as the Company’s Medical/Scientific Officer. Dr. Katz is a Professor of Emergency Medicine at the University of North Carolina at Chapel Hill, where he also conceived and managed the translational research program that produced the discovery of HBN-1 and the completion of a comprehensive 6 year pre-clinical program studying and refining its controlled hypothermia properties. Dr. Katz is Co-Director of the Carolina Resuscitation Research Group and also has extensive experience running acute medicine clinical trials (hospital and pre-hospital).

Email him at

Ron Tribble, DMDRon Tribble, DMD
Senior Business Advisor

Dr. Tribble spent 27 years in private dental practice followed by a position with Advantage Dental as their Dental Director, a Senior Management role. The position combined dental practice experience with knowledge from serving on several boards of directors, working in project management, and managing land development opportunities. Ron is an Investor in Hibernaid, serves on the Company’s Board of Directors and in the capacity of Senior Business Advisor to the CEO. In additions to his advisory and Board duties, Ron assists in identifying and pursuing non-dilutive grant opportunities for programs in the Hibernaid pipeline. Ron is a graduate of the OHSU School of Dentistry, having earned a Doctor of Medicine in Dentistry (DMD) degree.

Email him at

Samn RaffanielloSamn Raffaniello
VP, Administrative Systems and Support Services

Samn Raffaniello is VP, Administrative Systems and Support Services. Ms. Raffaniello has co-founded three start-ups in the past 18 years where her operational roles included project management/systems; budget/finance; drug manufacturing oversight; and contracts/IP management. A graduate of the University of Maryland, Ms. Raffaniello has 10 years prior Big Pharma experience in technical and business support of global drug development.

Email her at